Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
PharmacoEconomics is Scopus-indexed (Q1, CiteScore 8.5), ABDC A, ABS / AJG 2, WoS SCIE/SSCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer International Publishing.
Checked against the index lists dated .
ISSN 1170-7690Verify ISSN ↗1179-2027Verify ISSN ↗
Publisher: Springer International Publishing
Cost to publish: About US$4,990 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Health Policy | 16 / 330 | 95th | Q1 |
| Public Health, Environmental and Occupational Health | 44 / 725 | 94th | Q1 |
| Pharmacology | 53 / 328 | 83rd | Q1 |
Not listed in: DOAJ, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1992–present, best quartile Q1, CiteScore 8.5.
PharmacoEconomics is Q1 in Health Policy (rank 16 of 330), Q1 in Public Health, Environmental and Occupational Health (rank 44 of 725) and Q1 in Pharmacology (rank 53 of 328), by CiteScore 2025.
PharmacoEconomics is indexed in the Science Citation Index Expanded and Social Sciences Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.5, which places it in quartile Q1 at the 95th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.807, quartile Q1, with an H-index of 127.
The publisher lists an article processing charge of about US$4,990 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
PharmacoEconomics is published by Springer International Publishing. Its print ISSN is 1170-7690 and its online ISSN is 1179-2027.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded and Social Sciences Citation Index.
It is rated A in the ABDC Journal Quality List 2025 under Other economics.
It is graded 2 in the Chartered Association of Business Schools (ABS) Academic Journal Guide (AJG) 2024, in the Economics, Econometrics and Statistics field, unchanged from 2021.
No — it is not registered as an open-access journal in DOAJ or Scopus.
PharmacoEconomics has an h-index of 155 and a 2-year mean of 3.67 citations per paper (OpenAlex). Its Scopus CiteScore is 8.5, quartile Q1. On 2-year citations it ranks #40 of 327 Scopus journals in Health Policy.
PharmacoEconomics published 110 papers in 2025; its busiest recent year was 2018 with 142. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United Kingdom (29%), United States (17.2%) and Australia (10.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.